Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

Abstract: A film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and one or more cannabinoids, such as ?9-tetrahydrocannabinol (THC) or cannabidiol (CBD), or pharmaceutically acceptable salts thereof is described. Methods for manufacturing such a film, and the use of such a film in the treatment of disease are also described.

Abstract: A film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a triptan or a pharmaceutically acceptable salt thereof, are described. Methods for manufacturing such a film, and the use of such a film in the treatment of disease in a human patient, in particular migraine with or without aura, cluster headache, or trigeminal neuralgia, are also described.

Abstract: The present invention relates to films comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a compound of Formula (I), such as ketamine, or a pharmaceutically acceptable salt thereof. The present invention further relates to methods for manufacturing such films, and the use of such films in anesthesia, pain management, and the treatment of disease, in particular amnesia, depression and bipolar disorder.

Abstract: The present invention relates to films comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a carrier system comprising (a) a carrier, (b) a pathogen entry protein or fragment thereof, which specifically binds to a molecule on the surface of a mammalian target cell of said pathogen and which is covalently linked to the surface of said carrier, and (c) at least one active pharmaceutical ingredient. The present invention further relates to methods for manufacturing such films, and the use of such films in the treatment of a human patient.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

Abstract: A dissolution device for measuring a dissolution rate of a test sample in a fluid, the device comprising a first cavity and a second cavity, wherein each of the first and second cavities has a fluid inlet for connection to a fluid supply, and wherein the device comprises an opening between the first and second cavities, and the device comprises a sample support configured to position the test sample across the opening.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a compound of Formula (I), such as adrenaline, or a pharmaceutically acceptable salt thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of a condition selected from anaphylaxis, superficial bleeding and cardiac arrest.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and one or more cannabinoids, such as ?9-tetrahydrocannabinol (THC) or cannabidiol (CBD), or pharmaceutically acceptable salts thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of disease.

Abstract: A film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a triptan or a pharmaceutically acceptable salt thereof, are described. Methods for manufacturing such a film, and the use of such a film in the treatment of disease in a human patient, in particular migraine with or without aura, cluster headache, or trigeminal neuralgia, are also described.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a triptan or a pharmaceutically acceptable salt thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of disease in a human patient, in particular migraine with or without aura, cluster headache, or trigeminal neuralgia.

Abstract: A method of manufacturing a nicotine-containing mucoadhesive film, by preparing an aqueous solution at a pH of from 9.5 to 13, said solution comprising (i) a nicotine salt, (ii) an alkaline pH-regulating agent, and (iii) a film-forming agent comprising an alginate salt of monovalent cation or a mixture of alginate salts of monovalent cations, the film-forming agent having a mean guluronate (G) content of from 50 to 85% by weight, a mean mannuronate (M) content of from 15 to 50% by weight, a mean molecular weight of from 30,000 g/mol to 90,000 g/mol and being such that a 10% aqueous solution thereof at a temperature of 20° C. has a viscosity of 100-1000 mPas, as measured at a shear rate of 20 rpm by use of a Brookfield viscometer with a spindle No. 2; distributing the solution onto a solid surface; and permitting the solution to dry on said surface. A nicotine-containing mucoadhesive film.

Abstract: A method of preparing a mucoadhesive film containing vardenafil or a pharmaceutically acceptable salt of vardenafil, by admixing, in an aqueous liquid carrier, vardenafil or a pharmaceutically acceptable salt of vardenafil, a C3-C12 polyol, and a pH regulating agent, to obtain a liquid composition having a pH of at least 4.2; admixing the liquid composition with analginate salt of monovalent cation or a mixture of such salts, distributing the obtained composition onto a solid surface; and permitting the composition to dry. A mucoadhesive film containing vardenafil or a pharmaceutically acceptable salt of vardenafil, its use for treating sexual dysfunction.

Abstract: A method of manufacturing a nicotine-containing mucoadhesive film, by preparing an aqueous solution at a pH of from 9.5 to 13, the solution includes (i) a nicotine salt, (ii) an alkaline pH-regulating agent, and (iii) a film-forming agent including an alginate salt of monovalent cation or a mixture of alginate salts of monovalent cations, the film-forming agent having a mean guluronate (G) content of from 50 to 85% by weight, a mean mannuronate (M) content of from 15 to 50% by weight, a mean molecular weight of from 30,000 g/mol to 90,000 g/mol and being such that a 10% aqueous solution thereof at a temperature of 20° C. has a viscosity of 100-1000 mPas, as measured at a shear rate of 20 rpm by use of a Brookfield viscometer with a spindle No. 2; distributing the solution onto a solid surface; and permitting the solution to dry on said surface. A nicotine-containing mucoadhesive film.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a triptan or a pharmaceutically acceptable salt thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of disease in a human patient, in particular migraine with or without aura, cluster headache, or trigeminal neuralgia.

Abstract: A method of manufacturing a nicotine-containing mucoadhesive film, by preparing an aqueous solution at a pH of from 9.5 to 13, the solution includes (i) a nicotine salt, (ii) an alkaline pH-regulating agent, and (iii) a film-forming agent including an alginate salt of monovalent cation or a mixture of alginate salts of monovalent cations, the film-forming agent having a mean guluronate (G) content of from 50 to 85% by weight, a mean mannuronate (M) content of from 15 to 50% by weight, a mean molecular weight of from 30,000 g/mol to 90,000 g/mol and being such that a 10% aqueous solution thereof at a temperature of 20° C. has a viscosity of 100-1000 mPas, as measured at a shear rate of 20 rpm by use of a Brookfield viscometer with a spindle No. 2; distributing the solution onto a solid surface; and permitting the solution to dry on said surface. A nicotine-containing mucoadhesive film.

Abstract: An oral delivery product comprises a semi-permeable pouch designed for being placed in the oral cavity of a subject. The pouch encloses multiple solid particles of an alginate salt of monovalent cation comprising a biologically active substance comprised in the matrix formed by the alginate salt in the particles.

Abstract: An oral delivery product comprising a semi-permeable pouch designed for delivery of an active agent in the oral cavity of a subject. The pouch encloses multiple particles, and the particles are alginate matrices that comprise an active agent, e.g. nicotine. The alginate is e.g. sodium alginate, such as PROTANAL® LFR 5/60 or PROTANAL® LF 10/60.